Snuderl, Matija <br/><br/>
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.  [electronic resource] 

 -  The American journal of surgical pathology  Mar 2010 
 - 327-40 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-0979 
<br/><br/><label>Standard No.: </label>10.1097/PAS.0b013e3181cd3aeb  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Burkitt Lymphoma--classification<br/>Child<br/>Drug Resistance, Neoplasm<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Gene Rearrangement, B-Lymphocyte, Heavy Chain<br/>Genes, Immunoglobulin Heavy Chain<br/>Humans<br/>Immunophenotyping<br/>In Situ Hybridization, Fluorescence<br/>Kaplan-Meier Estimate<br/>Karyotyping<br/>Lymphoma, B-Cell--classification<br/>Lymphoma, Large B-Cell, Diffuse--classification<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Polymerase Chain Reaction<br/>Predictive Value of Tests<br/>Proportional Hazards Models<br/>Proto-Oncogene Proteins c-bcl-2--genetics<br/>Proto-Oncogene Proteins c-myc--genetics<br/>Retrospective Studies<br/>Risk Assessment<br/>Terminology as Topic<br/>Time Factors<br/>Treatment Outcome<br/>World Health Organization<br/>Young Adult